CAHptain Study
Contact
Description
The primary purpose of the CAHptain study is to explore the safety and efficacy of tildacerfont in children and adolescents aged 2 to 17 years of age with classic CAH, and evaluate if it may improve hormonal balance and allow children to take lower doses of glucocorticoids.
Eligibility and criteria
IRB Number:
22-020689
Eligible age range:
Clinical trial phase:
Phase II
Official title:
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.